Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9056 dose-ranging vs placebo (with open-label etanercept) in rheumatoid arthritis
2007-001420-12Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD9056 in rheumatoid arthritis (RA) (6 arms), sponsored by AstraZeneca. Primary endpoint: ACR20 response at 6 months (Visit 8). Started Jul 2007; status: completed.
02
Drugs
AZD9056
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-001420-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001420-12.